Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis

Exclusion Criteria

• •Participants who have been diagnosed with cancer within the last 3 years need to have appropriate negative cancer screening as per local standard of care within 6 months before Screening (basal or squamous cell skin cancer or carcinoma in situ of the cervix needs to have been excised and without evidence of residual disease for at least 3 months before Screening).
• •Evidence of active malignant disease or malignancies diagnosed within the previous 3 years including hematological malignancies and solid tumors.
• •Participants with other forms of myositis.
• •As per investigator discretion, participants with significant muscle damage (for example, severe muscle atrophy, end stage muscle disease, MRI with severe atrophy or fibrofatty replacement)
• •History of Neisseria meningitidis infection.
• •Human immunodeficiency virus (HIV) infection (evidenced by HIV Type 1 or Type 2 antibody titer).
• •Active systemic bacterial, viral, or fungal infection within 14 days prior to ravulizumab administration.
• •Presence of fever ≥ 38°Celsius (100.4°Fahrenheit) within 7 days prior to study drug administration on Day 1.
• •History of hypersensitivity to murine proteins or to 1 of the excipients of ravulizumab.
• •Pregnant, breastfeeding, or intending to conceive during the course of the study.
• •Inability or unwillingness to adhere to the protocol requirements.